MovDisordV3, Main, Exploration, bibRecordById, ISTEX:1345D2484372C026691E414E324F46CF716BD112

Psychosis in Parkinson's disease

Identifieur interne : 003F81 ( Main/Exploration ); précédent : 003F80; suivant : 003F82

Psychosis in Parkinson's disease

Auteurs : Werner Poewe [Autriche]

Source :

Movement Disorders [ 0885-3185 ] ; 2003-09.

RBID : ISTEX:1345D2484372C026691E414E324F46CF716BD112

Descripteurs français

Pascal (Inist)
- Article synthèse, Chimiothérapie, Homme, Neuroleptique, Parkinson maladie, Prévalence, Psychose, Symptomatologie, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antipsychotic Agents (therapeutic use), Chemotherapy, Cholinesterase Inhibitors (therapeutic use), Clinical Trials as Topic, Diagnosis, Differential, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Human, Humans, Neuroleptic, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Prevalence, Psychoses, Substance-Induced (diagnosis), Psychoses, Substance-Induced (drug therapy), Psychosis, Psychotic Disorders (diagnosis), Psychotic Disorders (drug therapy), Review, Risk Factors, Symptomatology, Treatment, atypical neuroleptics, cholinesterase inhibitors, hallucination, psychosis.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists.
- chemical , therapeutic use : Antiparkinson Agents, Antipsychotic Agents, Cholinesterase Inhibitors, Dopamine Agonists.
- diagnosis : Parkinson Disease, Psychoses, Substance-Induced, Psychotic Disorders.
- drug therapy : Parkinson Disease, Psychoses, Substance-Induced, Psychotic Disorders.
- Clinical Trials as Topic, Diagnosis, Differential, Humans, Risk Factors.

Abstract

Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital‐based series. Age, cognitive dysfunction, depression, as well as severity and duration of disease have all been identified as risk factors in multiple studies. All major antiparkinsonian drugs can induce psychosis in at‐risk patients. Early drug‐induced psychosis has been observed in up to 16% of patients treated with dopamine agonists and has been associated with increased risk for the development of dementia later on. Management of psychosis in PD is complex and includes control of potential triggers and reductions of polypharmacy as well as the addition of atypical antipsychotics. Cholinesterase inhibitors may prove an additional option in psychotic PD patients with dementia. © 2003 Movement Disorder Society

Url:

https://api.istex.fr/document/1345D2484372C026691E414E324F46CF716BD112/fulltext/pdf

DOI: 10.1002/mds.10567

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Psychosis in Parkinson's disease</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1345D2484372C026691E414E324F46CF716BD112</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10567</idno>
<idno type="url">https://api.istex.fr/document/1345D2484372C026691E414E324F46CF716BD112/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000F72</idno>
<idno type="wicri:Area/Istex/Curation">000F72</idno>
<idno type="wicri:Area/Istex/Checkpoint">002911</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Poewe W:psychosis:in:parkinson</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:14502660</idno>
<idno type="wicri:Area/PubMed/Corpus">003708</idno>
<idno type="wicri:Area/PubMed/Curation">003708</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003673</idno>
<idno type="wicri:Area/Ncbi/Merge">000B56</idno>
<idno type="wicri:Area/Ncbi/Curation">000B56</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B56</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Poewe W:psychosis:in:parkinson</idno>
<idno type="wicri:Area/Main/Merge">005C04</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:04-0080436</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002382</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000939</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002352</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Poewe W:psychosis:in:parkinson</idno>
<idno type="wicri:Area/Main/Merge">005E98</idno>
<idno type="wicri:Area/Main/Curation">003F81</idno>
<idno type="wicri:Area/Main/Exploration">003F81</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Psychosis in Parkinson's disease</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, University of Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2003-09">2003-09</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">S6</biblScope>
<biblScope unit="supplement">6</biblScope>
<biblScope unit="page" from="80">80</biblScope>
<biblScope unit="page" to="87">87</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">1345D2484372C026691E414E324F46CF716BD112</idno>
<idno type="DOI">10.1002/mds.10567</idno>
<idno type="ArticleID">MDS10567</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Cholinesterase Inhibitors (therapeutic use)</term>
<term>Clinical Trials as Topic</term>
<term>Diagnosis, Differential</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Human</term>
<term>Humans</term>
<term>Neuroleptic</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Prevalence</term>
<term>Psychoses, Substance-Induced (diagnosis)</term>
<term>Psychoses, Substance-Induced (drug therapy)</term>
<term>Psychosis</term>
<term>Psychotic Disorders (diagnosis)</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Review</term>
<term>Risk Factors</term>
<term>Symptomatology</term>
<term>Treatment</term>
<term>atypical neuroleptics</term>
<term>cholinesterase inhibitors</term>
<term>hallucination</term>
<term>psychosis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Antipsychotic Agents</term>
<term>Cholinesterase Inhibitors</term>
<term>Dopamine Agonists</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term>
<term>Psychoses, Substance-Induced</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Psychoses, Substance-Induced</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Diagnosis, Differential</term>
<term>Humans</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Article synthèse</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Neuroleptique</term>
<term>Parkinson maladie</term>
<term>Prévalence</term>
<term>Psychose</term>
<term>Symptomatologie</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital‐based series. Age, cognitive dysfunction, depression, as well as severity and duration of disease have all been identified as risk factors in multiple studies. All major antiparkinsonian drugs can induce psychosis in at‐risk patients. Early drug‐induced psychosis has been observed in up to 16% of patients treated with dopamine agonists and has been associated with increased risk for the development of dementia later on. Management of psychosis in PD is complex and includes control of potential triggers and reductions of polypharmacy as well as the addition of atypical antipsychotics. Cholinesterase inhibitors may prove an additional option in psychotic PD patients with dementia. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
</country>
<region><li>Tyrol (Land)</li>
</region>
<settlement><li>Innsbruck</li>
</settlement>
<orgName><li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F81 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003F81 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:1345D2484372C026691E414E324F46CF716BD112
   |texte=   Psychosis in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Psychosis in Parkinson's disease

Psychosis in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.